LOX-1 Ligand Binding for PMN-MDSC Isolation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for distinguishing polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) from polymorphonuclear neutrophils (PMNs) in biological fluids are complex, time-consuming, and inaccurate, often requiring multiple gradient separations and multi-color flow cytometry, and are difficult to standardize due to variations in cell density influenced by collection conditions.
Innovation Solution
A method involving contacting a biological fluid sample with a ligand that specifically binds or forms a complex with LOX-1 on the cell surface, allowing for the detection and isolation of PMN-MDSCs by distinguishing LOX-1-bound cells from other cells, enabling their tracking, differentiation, and enrichment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If multiple gradient separations and multi-color flow cytometry are used to distinguish PMN-MDSCs from PMNs, then measurement precision is improved, but device complexity and time consumption increase
Solution Approach 1:
The patent extracts and utilizes the specific biological characteristic (LOX-1 expression) that distinguishes PMN-MDSCs from PMNs. By focusing on this single key differentiating feature rather than attempting to separate cells based on density or use multiple markers, the method simplifies the detection process while maintaining accuracy. The LOX-1 specific antibody serves as a targeted extraction of the distinguishing characteristic.
Solution Approach 2:
The patent changes the detection parameter from physical properties (density, morphology) to a specific biological marker expression (LOX-1). This parameter change allows for direct immunological detection using flow cytometry with a single specific antibody, replacing complex gradient separation and multi-color analysis while improving both simplicity and accuracy.
2Quantity of substance
If gradient separation is used to separate PMN-MDSCs from PMNs, then separation is achieved, but reliability decreases due to density variations
Solution Approach 1:
The patent replaces the mechanical separation system (density gradient centrifugation) with an immunological recognition system. Instead of relying on physical density differences that vary with cell state, the method uses specific antibody-antigen recognition of LOX-1, which is constitutively expressed on PMN-MDSCs. This substitution eliminates the reliability issues associated with mechanical separation while maintaining effective cell identification and separation.
3Manufacturing precision
If multiple gradient separations are performed, then cell separation is improved, but time consumption increases
Solution Approach 1:
The patent performs preliminary identification by staining cells with LOX-1 specific antibody before any separation step. This preliminary action allows for direct identification of PMN-MDSCs through their unique marker expression, eliminating the need for multiple sequential gradient separations. The time-consuming iterative separation process is replaced by a single staining and detection step.
Solution Approach 2:
The method extracts the key identifying feature (LOX-1 expression) and uses it as the sole basis for cell identification and separation. This extraction of the essential differentiating characteristic eliminates the need for multiple separation steps, thereby reducing time consumption while maintaining separation purity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively differentiates and isolates PMN-MDSCs from PMNs, providing a more accurate and efficient method for monitoring and diagnosing cancer by identifying cells that form a complex with the LOX-1 reagent, which correlates with cancer presence and progression.
Implementation Method 1
contacting a biological fluid sample from the subject containing polymorphonuclear neutrophils (PMNs) and polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) with a ligand that specifically binds or forms a complex with LOX-1 on the cell surface
Data Source
AI summary
A method of obtaining a population of cells enriched in human polymorphonuclear myeloid derived suppressor cells (PMN-MDSCs) comprises isolating from a cell suspension those cells which express LOX-1 to provide a population of cells enriched with PMN-MDSCs. A method of monitoring the population of LOX-1+ cells in a cell-containing biological sample is useful for determining the efficacy of treatment or the metastasis or increasing progression of cancer. Other cell isolation and diagnostic methods are also described.